Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672715 | 1.00 | LSS (0.78) | LSS | |
| SCHEMBL9360244 | 0.89 | LSS (0.80) | LSS | |
| SCHEMBL7681511 | 0.88 | LSS (1.00) | LSS | |
| SCHEMBL3735360 | 0.88 | LSS (0.78) | LSS | |
| SCHEMBL3735362 | 0.88 | LSS (0.78) | LSS | |
| SCHEMBL7681518 | 0.88 | LSS (1.00) | LSS | |
| SCHEMBL7681522 | 0.88 | LSS (1.00) | LSS | |
| Bromide SCHEMBL7677221 | 0.87 | LSS (0.98) | LSS | |
| Bromide SCHEMBL7677213 | 0.87 | LSS (0.98) | LSS | |
| SCHEMBL3674915 | 0.86 | LSS (0.75) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0636367-B1 | Use of phenylalkylamines for producing cholesterol lowering agents | HOFFMANN LA ROCHE (CH) | 2000-03-29 | — | — | EP | claimed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| US-5637771-A | Compound useful for lowering cholesterol | HOFFMANN-LA ROCHE INC. (US) | 1997-06-10 | — | — | US | disclosed |
| US-5574071-A | ADMINISTERING PHENYLALKYLAMINO KETONES | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5495048-A | ANTICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | LSS 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.